【研究室主要論文】
・Fujiwara N, Matsushita Y, Tempaku M, Tachi Y, Kimura G, Izuoka K, Hayata Y, Kawamura S, Eguchi A, Nakatsuka T, Sato M, Ono A, Murakami E, Tsuge M, Oka S, Hayashi A, Hirokawa Y, Watanabe M, Parikh ND, Singal AG, Marrero JA, Hoshida Y, Mizuno S, Tateishi R, Koike K, Fujishiro M, Nakagawa H. AI-based phenotyping of hepatic fiber morphology to inform molecular alterations in metabolic dysfunction-associated steatotic liver disease. Hepatology. 2025. doi: 10.1097/HEP.0000000000001360.
・Nagaoki Y, Yamaoka K, Fujii Y, Uchikawa S, Fujino H, Ono A, Murakami E, Kawaoka T, Miki D, Aikata H, Hayes CN, Tsuge M, Oka S. Impact of viral eradication by direct-acting antivirals on clinical outcomes after curative treatment for hepatitis C virus-associated hepatocellular carcinoma. Therap Adv Gastroenterol. 18:17562848251324094, 2025.
・Kosaka M, Fujino H, Tsuge M, Yamaoka K, Fujii Y, Uchikawa S, Ono A, Murakami E, Kawaoka T, Miki D, Hayes CN, Kashiyama S, Mokuda S, Yamazaki S, Oka S. Usefulness of serum HBV RNA levels for predicting antiviral response to entecavir treatment in patients with chronic hepatitis B. J Gastroenterol. 60(4): 469-478, 2025.
・Bao H, Murakami S, Tsuge M, Uchida T, Uchikawa S, Fujino H, Ono A, Murakami E, Kawaoka T, Miki D, Hayes CN, Oka S. Alteration of Gene Expression After Entecavir and Pegylated Interferon Therapy in HBV-Infected Chimeric Mouse Liver. Viruses. 16(11): 1743, 2024.
・Nakahara H, Ono A, Hayes CN, Shirane Y, Miura R, Fujii Y, Murakami S, Yamaoka K, Bao H, Uchikawa S, Fujino H, Murakami E, Kawaoka T, Miki D, Tsuge M, Oka S; Hiroshima Liver Study Group; TransSCOT Consortium. Prediction of Hepatocellular Carcinoma After Hepatitis C Virus Sustained Virologic Response Using a Random Survival Forest Model. JCO Clin Cancer Inform. 8: e2400108, 2024.
・Miura R, Ono A, Nakahara H, Shirane Y, Yamaoka K, Fujii Y, Uchikawa S, Fujino H, Murakami E, Kawaoka T, Miki D, Tsuge M, Kishi T, Ohishi W, Sakamoto N, Arihiro K, Hayes CN, Oka S. Serum IL-6 concentration is a useful biomarker to predict the efficacy of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma. J Gastroenterol. 60(3): 328-339, 2025.
・Shirane, Y., Fujii, Y., Ono, A., Nakahara, H., Hayes, C.N., Miura, R., Murakami, S., Sakamoto, N., Uchikawa, S., Fujino, H., Nakahara, T., Murakami, E., Yamauchi, M., Miki, D., Kawaoka, T., Arihiro, K., Tsuge, M., and Oka, S., Peripheral T Cell Subpopulations as a Potential Surrogate Biomarker during Atezolizumab plus Bevacizumab Treatment for Hepatocellular Carcinoma. Cancers, 2024. 16(7).
・Duehren, S., Uchida, T., Tsuge, M., Hiraga, N., Uprichard, S.L., Etzion, O., Glenn, J., Koh, C., Heller, T., Cotler, S.J., Oka, S., Chayama, K., and Dahari, H., Interferon alpha induces a stronger antiviral effect than interferon lambda in HBV/HDV infected humanized mice. Virus Res 349: p. 199451, 2024.
・Hiyama, Y., Fujino, H., Namba, M., Fujii, Y., Uchikawa, S., Ono, A., Nakahara, T., Murakami, E., Kawaoka, T., Miki, D., Tsuge, M., and Oka, S., Value of autotaxin for hepatocellular carcinoma risk assessment in chronic hepatitis B patients treated with nucleos(t)ide analogs. Hepatology Research, 2024.
・Yamauchi M, Ono A, Amioka K, Fujii Y, Nakahara H, Teraoka Y, Uchikawa S, Fujino H, Nakahara T, Murakami E, Okamoto W, Miki D, Kawaoka T, Tsuge M, Imamura M, Hayes CN, Ohishi W, Kishi T, Kimura M, Suzuki N, Arihiro K, Aikata H, Chayama K, Oka S. Lenvatinib activates anti-tumor immunity by suppressing immunoinhibitory infiltrates in the tumor microenvironment of advanced hepatocellular carcinoma. Commun Med (Lond) 3(1): 152, 2023.
・Hailegiorgis A, Ishida Y, Collier N, Imamura M, Shi Z, Reinharz V, Tsuge M, Barash D, Hiraga N, Yokomichi H, Tateno C, Ozik J, Uprichard SL, Chayama K, Dahari H. Modeling suggests that virion production cycles within individual cells is key to understanding acute hepatitis B virus infection kinetics. PLoS Comput Biol 19(8): e1011309, 2023.
・Suehiro Y, Tsuge M, Kurihara M, Uchida T, Fujino H, Ono A, Yamauchi M, Naswa Makokha G, Nakahara T, Murakami E, Abe-Chayama H, Kawaoka T, Miki D, Imamura M, Aikata H, Nelson Hayes C, Fujita T and Chayama K. Hepatitis B Virus (HBV) Upregulates TRAIL-R3 Expression in Hepatocytes Resulting in Escape From Both Cell Apoptosis and Suppression of HBV Replication by TRAIL. J Infect Dis 227: 686-695, 2023.
・Murakami S, Imamura M, Uchida T, Suehiro Y, Namba M, Fujii Y, Uchikawa S, Teraoka Y, Fujino H, Ono A, Nakahara T, Murakami E, Okamoto W, Yamauchi M, Kawaoka T, Miki D, Hayes NC, Tsuge M, Aikata H, Ohira M, Ohdan H and Oka S. Serum interleukin-6 level predicts the prognosis for patients with alcohol-related acute-on-chronic liver failure. Hepatol Int 17: 1225-1232, 2023.
・Gad SA, Sugiyama M, Tsuge M, Wakae K, Fukano K, Oshima M, Sureau C, Watanabe N, Kato T, Murayama A, Li Y, Shoji I, Shimotohno K, Chayama K, Muramatsu M, Wakita T, Nozaki T and Aly HH. The kinesin KIF4 mediates HBV/HDV entry through the regulation of surface NTCP localization and can be targeted by RXR agonists in vitro. PLoS Pathog 18: e1009983, 2022.
・Tsuge M. Are humanized mouse models useful for basic research of hepatocarcinogenesis through chronic hepatitis B virus infection? Viruses, 13: 1920, 2021.
・Tsuge M. The association between hepatocarcinogenesis and intracellular alterations due to hepatitis B virus infection. Liver Int, 41(12): 2836-2848, 2021.

【教育内容】
ウイルス性肝疾患における抗ウイルス療法、肝臓癌における治療選択、胃・食道静脈瘤に対する内視鏡治療、急性・慢性肝不全症例の治療および肝移植に向けた全身管理など様々な肝疾患診療を行っている。特に、抗ウイルス療法効果不良例への対応や肝臓癌の化学療法、移植前の肝不全症例の管理は専門性が高く、他診療科や多職種との連携が不可欠であるため、肝臓専門医としての幅広い知識と技術を習得することができる。

【研究内容】
肝疾患に関する様々な基礎・臨床研究に取り組んでおります。
1．C型慢性肝疾患に対する抗ウイルス療法の治療成績と治療後の発癌や線維化進展に関する臨床研究
2．B型肝炎ウイルスの感染・複製のメカニズムおよび発癌メカニズムに関する基礎・臨床研究
3．肝炎ウイルス感染や肝発癌と遺伝子多型との関連解析
4．肝疾患症例における腸内細菌叢の変化に関する基礎研究
5．肝細胞癌に対する治療成績に関与する因子の基礎・臨床研究